title: Impaired NK cell development in an IFN-gamma transgenic mouse: aberrantly expressed IFN-gamma enhances hematopoietic stem cell apoptosis and affects NK cell differentiation.
abstract: Aberrant expression of IFN-gamma has been demonstrated to cause a wide variety of alterations in cell function and development. Previously we reported that constitutive expression of IFN-gamma in bone marrow (BM) and thymus results in a total absence of B cells and a substantial decrease in the number of hematopoietic progenitor cells. In this study, we demonstrate a severe deficiency of NK1.1(+)CD3(-) cells in this transgenic mouse model. Compared with normal control littermates, we found a pronounced reduction of NK cells in IFN-gamma transgenic mouse spleen and liver despite maintenance of normal function. In addition, we observed a reduced number of BM cells in the IFN-gamma transgenic mouse despite normal expression of hematopoietic growth factors in the BM. Interestingly, these cells were less responsive to stem cell factor (SCF) despite c-kit expression on hematopoietic stem cells (HSCs). We observed that addition of exogenous IFN-gamma inhibited proliferation of HSCs and differentiation of NK precursors from HSCs in normal mice in response to SCF, IL-7, fms-like tyrosine kinase 3 ligand, and IL-15. Furthermore, we found that HSCs express the IFN-gammaRalpha subunit and undergo apoptosis in response to exogenous IFN-gamma. Thus, we have demonstrated the occurrence of a severe deficiency of NK cells and lower numbers of BM cells in an IFN-gamma transgenic mouse model. Furthermore, because exogenous IFN-gamma affects the responsiveness to hematopoietic growth factors such as SCF in vitro, our results indicate that chronic expression of IFN-gamma in vivo leads to widespread immune system defects, including alterations in NK cell differentiation.
authors.affiliation: Laboratory of Experimental Immunology, Center for Cancer Research, and Intramural Research Support Program, Science Applications International Corp.-Frederick, National Cancer Institute, Frederick, MD 21702, USA.
authors.forename: Osamu
authors.initials: O
authors.lastname: Shimozato
authors.forename: John R
authors.initials: JR
authors.lastname: Ortaldo
authors.forename: Kristin L
authors.initials: KL
authors.lastname: Komschlies
authors.forename: Howard A
authors.initials: HA
authors.lastname: Young
mesh_terms: D000818:Animals; D017209:Apoptosis; D002452:Cell Count; D002454:Cell Differentiation; D002478:Cells, Cultured; D016207:Cytokines / Q000096:biosynthesis; D003601:Cytotoxicity Tests, Immunologic; D005434:Flow Cytometry; D006412:Hematopoietic Stem Cells / Q000145:classification / Q000276:immunology*; D016130:Immunophenotyping; D007371:Interferon-gamma / Q000235:genetics* / Q000378:metabolism / Q000502:physiology*; D007694:Killer Cells, Natural / Q000145:classification / Q000276:immunology*; D008565:Membrane Proteins / Q000494:pharmacology; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic
chemical_list: D016207:Cytokines; D008565:Membrane Proteins; C084881:flt3 ligand protein; D007371:Interferon-gamma